Annual report pursuant to Section 13 and 15(d)

Note 17 - Material Agreements (Details Textual)

v3.21.1
Note 17 - Material Agreements (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 31, 2014
Nov. 30, 2009
Jan. 31, 2002
Dec. 31, 2020
Dec. 31, 2019
Research and Development Expense, Total       $ 4,930,187 $ 5,338,267
Reliable Supply Agreement [Member]          
Long-term Contract for Supplies, Option to Extend, Term (Year)   3 years      
Tc99m Tilmanocept License Agreement [Member]          
License Issue Fee     $ 25,000    
License Maintenance Fee     25,000    
Minimum Annual Royalty     $ 25,000    
Expanded Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | Cost of Sales [Member] | License [Member]          
Cost of Goods and Services Sold, Total       1,000 2,000
Amended and Restated Tilmanocept License Agreement [Member]          
Research and Development Expense, Total       34,000 191,000
Tilmanocept License Agreement [Member]          
License Issue Fee $ 25,000        
License Maintenance Fee 25,000        
Minimum Annual Royalty $ 25,000        
Research and Development Expense, Total       275,000 $ 355,000
Employment Agreement [Member] | Maximum [Member]          
Loss Contingency, Estimate of Possible Loss       $ 2,500,000